SCHEDULE: State Street Reports 5.5% Stake in Compass Therapeutics

State Street Corporation has disclosed beneficial ownership of 5.5% of Compass Therapeutics' common stock as of June 30, 2026.

Summary

• State Street Corporation has filed a Schedule 13G, indicating it beneficially owns 9,953,653 shares of Compass Therapeutics' common stock.
• This ownership represents 5.5% of the class of securities.
• The filing details shared voting power of 9,687,331 shares and shared power to dispose of 9,953,653 shares.
• The reporting entity is State Street Corporation, organized in Massachusetts.
• The filing date is August 7, 2026, with the event date requiring the filing being June 30, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without significant new strategic or financial information.

Positives

• State Street Corporation's investment indicates confidence in Compass Therapeutics' long-term prospects from a significant institutional investor.
• The disclosure provides transparency regarding a substantial shareholder's holdings.

Negatives

• The filing does not provide any new operational or financial performance data for Compass Therapeutics.
• The information is purely a reporting of beneficial ownership, offering no insight into the company's current business activities or future plans.

Risks

• Potential for future stock sales by State Street Corporation could impact share price.
• Concentration of ownership among a few large holders can sometimes lead to reduced liquidity.

Future Outlook

This filing does not contain forward-looking statements or guidance from Compass Therapeutics. It solely reports on the ownership status of State Street Corporation.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. This filing indicates State Street Corporation's role as a major holder in the biotechnology sector, specifically within Compass Therapeutics.

Stakeholder Impact

• Shareholders: Increased transparency regarding a significant institutional holder may influence investor sentiment.
• Company Management: May need to engage with State Street Corporation on strategic matters due to their substantial stake.

Next Steps

• Monitor future filings from State Street Corporation for any changes in beneficial ownership.
• Observe Compass Therapeutics' strategic developments and financial performance for insights into the company's valuation.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, State Street Corporation, Compass Therapeutics, Institutional Investor, Common Stock, Investment Holding